Email from NNLX with full Tribune Chronicle articl
Post# of 9144
Posted On: 12/22/2015 8:55:18 PM
Email from NNLX with full Tribune Chronicle article.
Full credit for this article is to the Warren Tribune Chronicle, Warren, Ohio
Local company customizes diagnostic tool for the globe
NanoLogix Inc. does biotechnology in Hubbard
December 22, 2015
By VIRGINIA SHANK - Tribune Chronicle , Tribune Chronicle
HUBBARD - NanoLogix Inc., a local biotechnology company, has been contracted to customize one of its diagnostic tools for a global medical device manufacturer.
Leaders of the Hubbard-based company, who made the announcement Monday, said they could not disclose the name of the manufacturer and / or additional information about the deal because of contract restrictions.
They said the manufacturer contacted NanoLogix in February, the agreement was finalized in late October and a purchase order was issued in late November. NanoLogix then began the initial customization of the N-Assay, a modified ELISA, or enzyme-linked immunosorbent assay.
Bret Barnhizer, NanoLogix CEO, said finalization of the contract is the most significant news the company has ever had.
Barnhizer said this initial customization of the N-Assay is the first of its kind for NanoLogix .
"The technology has proven to be the most accurate, fastest, and sensitive diagnostic tested, able to rapidly detect bacteria strains and determine whether or not those strains are resistant to various antibiotics," he said.
Barnhizer said the N-Assay has detected sub-strains of some bacteria that are not seen with traditional standard diagnostic tests.
"The significance of that development is that we can now recognize the existence of those sub-strains while others cannot, meaning that where previously a patient tested as negative for presence of a bacteria, he or she may be found to have a previously undetected infection," he said.
He said the financial implications are also significant as the company projects roughly $500,000 in sales and development funding from this venture, with other customized N-Assay kits in the planning stage for the same customer.
Additionally, NanoLogix is exploring options for expansion of its current facilities in Hubbard to accommodate manufacturing of the antibody-coated N-Assay.
NanoLogix is a biotechnology company focused primarily on both rapid diagnostics and petri plates. Its products offer accelerated detection and identification of microorganisms.
In addition to medical, national defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing, the company said.
ELISA is a diagnostic test that uses antibodies and color change to identify a substance. The N-Assay provides rapid, accurate, and sensitive detection and identification of any bacteria tested to date for which there exists an antibody, with the added capability of near-simultaneous determination of antibiotic sensitivity and resistance.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics and antibiotic sensitivity.
Full credit for this article is to the Warren Tribune Chronicle, Warren, Ohio
Local company customizes diagnostic tool for the globe
NanoLogix Inc. does biotechnology in Hubbard
December 22, 2015
By VIRGINIA SHANK - Tribune Chronicle , Tribune Chronicle
HUBBARD - NanoLogix Inc., a local biotechnology company, has been contracted to customize one of its diagnostic tools for a global medical device manufacturer.
Leaders of the Hubbard-based company, who made the announcement Monday, said they could not disclose the name of the manufacturer and / or additional information about the deal because of contract restrictions.
They said the manufacturer contacted NanoLogix in February, the agreement was finalized in late October and a purchase order was issued in late November. NanoLogix then began the initial customization of the N-Assay, a modified ELISA, or enzyme-linked immunosorbent assay.
Bret Barnhizer, NanoLogix CEO, said finalization of the contract is the most significant news the company has ever had.
Barnhizer said this initial customization of the N-Assay is the first of its kind for NanoLogix .
"The technology has proven to be the most accurate, fastest, and sensitive diagnostic tested, able to rapidly detect bacteria strains and determine whether or not those strains are resistant to various antibiotics," he said.
Barnhizer said the N-Assay has detected sub-strains of some bacteria that are not seen with traditional standard diagnostic tests.
"The significance of that development is that we can now recognize the existence of those sub-strains while others cannot, meaning that where previously a patient tested as negative for presence of a bacteria, he or she may be found to have a previously undetected infection," he said.
He said the financial implications are also significant as the company projects roughly $500,000 in sales and development funding from this venture, with other customized N-Assay kits in the planning stage for the same customer.
Additionally, NanoLogix is exploring options for expansion of its current facilities in Hubbard to accommodate manufacturing of the antibody-coated N-Assay.
NanoLogix is a biotechnology company focused primarily on both rapid diagnostics and petri plates. Its products offer accelerated detection and identification of microorganisms.
In addition to medical, national defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing, the company said.
ELISA is a diagnostic test that uses antibodies and color change to identify a substance. The N-Assay provides rapid, accurate, and sensitive detection and identification of any bacteria tested to date for which there exists an antibody, with the added capability of near-simultaneous determination of antibiotic sensitivity and resistance.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics and antibiotic sensitivity.
(0)
(0)